Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ORIC-114 Dose 1+ amivantamab · 1 trial · 4 indications
RP2D of ORIC-114 in combination with amivantamab by interval 3+3 dose escalation design
Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
| Arm | Type | Description |
|---|---|---|
| Part 1 Dose Escalation level 1 | EXPERIMENTAL | ORIC-114 + amivantamab |
| Part 1 Dose Escalation level 2 | EXPERIMENTAL | ORIC-114 + amivantamab |
| Part 1 Dose Escalation level 3 | EXPERIMENTAL | ORIC-114 + amivantamab |
| Part 2 Dose Expansion | EXPERIMENTAL | Two potential ORIC-114 dose levels + amivantamab |
| Name | Type | Description |
|---|---|---|
| ORIC-114 Dose 1 + amivantamab | DRUG | ORIC-114 oral daily, amivantamab subcutaneous weekly for 4 weeks followed by every 4 week injection |
| ORIC-114 Dose 2 + amivantamab | DRUG | ORIC-114 oral daily, amivantamab subcutaneous weekly for 4 weeks followed by every 4 week injection |
| ORIC-114 Dose 3 + amivantamab | DRUG | ORIC-114 oral daily, amivantamab subcutaneous weekly for 4 weeks followed by every 4 week injection |
Inclusion Criteria: * Histologically or cytologically confirmed metastatic NSCLC with a documented EGFR exon 20 insertion mutation as determined locally by any nucleic acid-based diagnostic testing method; all tests should be performed in a CLIA certified or equivalently accredited laboratory * Pri...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
ORIC-114 Dose 1+ amivantamab is an investigational combination therapy being studied for the treatment of solid tumors, specifically EGFR exon 20 insertion mutant non-small cell lung cancer (NSCLC). It is currently in Phase 1 clinical development for these indications.
ORIC-114 Dose 1+ amivantamab is being developed by Oric Pharmaceuticals, Inc., a biopharmaceutical company traded on the stock exchange under the ticker symbol ORIC. The company is conducting clinical trials to evaluate this combination therapy.
ORIC-114 Dose 1+ amivantamab is in Phase 1 clinical development. It is an investigational therapy and has not been approved by regulatory authorities. The ongoing Phase 1 trial is currently recruiting participants to evaluate its safety and efficacy.
ORIC-114 Dose 1+ amivantamab is being studied in a Phase 1 clinical trial with the identifier NCT06816992. This trial is titled 'ORIC-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR Exon20 Insertion Mutant NSCLC' and is currently recruiting participants.
Yes, ORIC-114 Dose 1+ amivantamab is the same as ORIC-114 Dose 1 + amivantamab. The two names refer to the identical investigational combination therapy being developed by Oric Pharmaceuticals for the treatment of solid tumors.